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ABSTRACT Sleep disorders is one of the most frequent child medical consultation, indeed the rate of
children that suffer it in a transitory way is considerably high. Among the most common sleep disorders is
named ’’children behavioral insomnia’’, many different drugs has been used as treatment with poor results
with relevant secondary effects. We focus on children with ADHD that present sleep disorders among
most frequent comorbidities. The most relevant contribution of this work is the use of an artificial neural
network (ANN) for unsupervised learning called the Growing Neural Forest (GNF), which is a variation of
the Growing Neural Gas (GNG) model where a set of trees is learnt instead of a general graph so that input
data can be better represented, to study actigraphic data to evaluate the use of MTF and melatonin in a group
of children with sleep disorders. Thus, the GNF model is trained with actigraphic data from children ADHD
affected as input data. The GNG and SOM (Self-Organizing Map) models are also trained with these data
for comparative purposes. Experimental results demonstrate that sleep was not affected by administrating
drugs (MFT and melatonin).
INDEX TERMS Artificial neural networks, application, children, melatonin, ADHD.
I. INTRODUCTION
Nowadays one of the most frequent child medical consulta-
tion is sleep disorders [24]. The rate of children that suffer it
in a transitory way in considerably high, even it is foreseen
that 30% children population suffer chronic alterations in
sleepwith a rate even higher than neurologic diseases affected
patients.
These problems are usually stables along infancy in such
a way that a child with sleep disorders in early 8 months it
is highly probably that he still shows difficulties in his third
year old. Similarly, those children with difficulties at two
years old, they will go on with sleep disorders at 12 years
old [58]. One on the most common sleep disorders are
named ‘‘children behavioral insomnia’’, which consists in
prolonged latency periods in initiating night sleeps and/or
prolonged and frequent awakens during second half of the
night 10, these problems are particularly frequent in ADHD
children [6], [16], [51]. Different drugs has been used as
treatment (antihistaminic, bariatrics, benzodiazepines, etc),
but these have numerous and important secondary effects:
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tachycardia, mucosa dryness, heavy feeling, amnesias, sleep
phases distortions, etc [29]. However, several works show
how melatonin (aMT) is a good sleep instigator that does not
present known secondary effects at the moment [20], [55],
[59]. We highlight Jan and O’Donell [28] reviews about the
use of aMT in children sleep disorders.
American Board of Sleep Medicine (ABSM) has claimed
actigraphy as an useful methodology to evaluate children
sleep disorders [35]. Its easy usage, dependability and cost
rate have led to a generalize usage and it is being used in
children with Asperger syndrome [61], disruption autistic
spectrum [39], attention deficit/hyperactivity [11] and sleep
disorders [7].
Children with ADHD presents sleep disorders among most
frequent comorbidities, which can be increased when we use
as treatment Metil-Fenidato (MTF) [13], [45]. Nevertheless,
this drug has some secondary effects that could affect on these
patients’ quality of life [14]. The main target of this work is
the use of an artificial neural network (ANN), which is fed
with actigraphic data from children with ADHD, in order to
evaluate whether combine administration of aMT and MFT
allows keeping or improving sleep pattern in those patients
before starting a treatment.
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Some recent works on ANN applied to Actigraphy
are found in the literature. Particularly, deep neural net-
works (NNs) have achieved, over last few years, state of
the art performance on a wide variety of machine learning
tasks in various domains such as speech recognition, com-
puter vision and natural language processing. Nevertheless,
there is a wave interested in adapting NNs to sleep/wake
state detection [8]. They use a Recurrent Neural Network for
multimodal ambulatory sleep detection.
Long et al. [36] present an actigraphy-based approach for
sleep/wake detection for insomniacs. They use actigraphy to
estimate overnight sleep-wake patterns in clinical practice
using a Cohen’s kappa from 0.49 to 0.55.
Hammerla et al. [22] present an approach for deep, convo-
lutional, and recurrent models for human activity recognition
using wearables as actigraphs. They focus on human activ-
ity recognition (HAR) in ubiquitous computing investigating
the suitability of each model for HAR, across thousands
of recognition experiments with randomly sampled model
configurations.
In [21] authors present an study with two novel mod-
eling schemes that utilize Deep Convolutional Neural Net-
works (CNN) to identify sleep/wake states. They propose
two methods of deep CNN for detecting the four sleep/wake
states in a raw activity data: sequential CNN, and Multi-Task
Learning (MTL) based approach. Their model takes advan-
tage of the reduced complexity of CNN architecture (relative
to RNN), while leveraging the inherent strength of CNN to
detect local motifs in a time augmented context.
All of these works focused on identifying different stages
in the sleep using ANN for this classification, our approach
focuses on valuing MTF and melatonin effect on ADHD
affected children. For this purpose, we have taken real values
from actigraphs of children with sleep disorders and we have
designed and implemented a GNF model to analyze if MTF
and melatonin affects the sleep of those children. Addition-
ally, we have designed and modeled GNG and SOM models
to perform a comparative of different alternatives with similar
results.
The structure of this paper is as follows. First the method-
ology used in this research is explained in Section II. Then
experimental results are presented in Section III. Some key
findings are discussed in Section IV. Finally, Section V is
devoted to conclusions.
II. METHODOLOGY
A. METHODS STUDY DESIGN
The study was an open label clinical trial involving a short
term follow up for 1 month. Participants came from the
Health Area of Granada (Spain). They received a suspected
diagnosis of ADHD from their primary care pediatrician
and were referred to the Neuropediatric, Neuropsychology
and Early Intervention Unit of San Cecilio University Hos-
pital (Granada) for subsequent monitoring and evaluation.
At the hospital, the same study protocol was followed by
all patients in order to reach the definitive diagnosis of
the ADHD and possible comorbidities. A complete medical
record and a careful physical examination were initially done.
The medical record was based on the interviews done to the
patient and parents, as well as the information provided by
the teachers. A neuropsychological assessment was carried
out in order to complement the diagnostic process, which
included the following questionnaires: the NICHQVanderbilt
Parent Assessment Scale [66] and the NICHQ Vanderbilt
Teacher Assessment Scale [3]; the Kaufman Brief Intelli-
gence Test [30] and the Wechsler Intelligence Scale for Chil-
dren [26] to assess the intelligence and the cognitive capacity;
the Magallanes Scale of Visual Attention [34] the Children’s
Depression Inventory [57] and the Spence Children’s. Anx-
iety Scale41. The final diagnosis of ADHD and the specific
subtype was made according to the Diagnostic and Statistical
Manual of Mental Disorders 5th edition (DSM-5).
The study protocol was approved by the local Ethical
Committee of Biomedical Research of Granada (Spain). All
procedures were carried out in accordance with the Helsinki
Declaration as revised in 2000 (World Medical Association
2000). Written informed consent signed by both parents or
tutors was required to participate in the study and to publish
the results, as well as the assent of school aged children
to their involvement in the research. The written informed
consent was also required from patients over 12 years and suf-
ficiently mature in relation to their developmental age. Exclu-
sion criteria to participate in our study included metabolic
or endocrine disorders as well as other neurological diseases
able to justify the present symptoms. However, comorbid
disorders with ADHD were not considered as exclusion cri-
teria. Patients taking medications that may disturb sleep or
alter the metabolism of orally administered melatonin were
not included either. Finally 27 children and adolescents with
ADHD were recruited. The sample consisted of 17 boys
(63%) and 10 girls (37%), aged 7-15 years (10+/− 2 years)
at start of the intervention period.
B. PROCEDURE
• Therapeutic intervention: once the diagnosis of ADHD
was confirmed, a multimodal treatment regimen was
designed based on the joint decision made by family,
teachers, psychologists and pediatricians of our unit.
The pharmacological treatment consisted of a com-
bined therapy with extended-release methylphenidate
hydrochloride (Concerta R, Janssen Pharmaceuti-
cals, Inc., Titusville, NJ, US) (initial daily dose of
1 mg/kg/day) and immediate release-acting melatonin
(dose of 1 mg administered 30 minutes before bed-
time). It was also added a nutritional supplement with
omega-3 fatty acids that contained eicosapentaenoic
acid (EPA) 70 mg/day and docosahexaenoic acid (DHA)
250 mg/day. All medications started at the same time.
Except melatonin, MPH and EPA/DHA were adminis-
tered in the morning in one single dose. Sleep diary:
in order to know the sleep habits of our patients,
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the official sleep diary validated by the National Sleep
Foundation (US) was completed by parents and ado-
lescents before starting treatment. The diary collected
information for a 7 day-period with identical questions
for each day: 1) bedtime; 2) get-up time; 3) sleep
onset; 4) night awakenings; 5) feeling at wake-up time
(refreshed, somewhat refreshed or fatigued); 6) sleep
duration; 7) sleep disturbances (any mental, emotional,
physical or environmental factors that affected sleep,
e.g., stress, snoring, physical discomfort, temperature);
8) caffeinated drink consumption; 9) physical exercise;
10) alcohol or a heavy meal intake 2-3 hours before
going to bed; 11) medication intake; 12) activity carried
out 1 hour before going to sleep (watch television, work,
read).
• Sleep questionnaire: before treatment, the parents com-
pleted the Pediatric Sleep Questionnaire (PSQ) short
version [62] translated into Spanish language. The PSQ
is designed to screen for sleep problems in children. The
shorter version specifically relates to sleep-disordered
breathing (SDB) in children, apart from containing
questions associated with symptoms of hyperactivity
and inattention. It consists of 22 parent-reported items
examining snoring and breathing problems, daytime
sleepiness, inattention, hyperactivity, and other pediatric
obstructive sleep apnea features. Responses are ‘‘yes′′ =
1, ‘‘no′′ = 0, and ‘‘unknown′′ = missing. The presence
of 8 or more positive responses suggests a possible
SDB [62].
• Actigraphy: actigraphs were used in sleep assessment to
discriminate between sleep wake states through infor-
mation provided by body movements. Actigraphs used
in this study (MotionWatch, Cambridge Neurotechnol-
ogy Ltd., Cambridge, UK) were worn on the non dom-
inant wrist 24 hours a day, for 7 consecutive days.
Recordings of the amount of movement were made at
0.5minute (30 second)-epoch and at the higher threshold
value of sensitivity (threshold value for each sensitivity
setting: low sensitivity= 80, medium sensitivity = 40,
high sensitivity = 20). The activity score for each
epoch was then compared to the threshold to determine
if the epoch was scored as wake or sleep (CamNtech Ltd
2016). This device model incorporated a light sensor to
record luminous intensity of white light and compare
this information with that one provided by sleep diary
in relation to bedtime and get-up time. The data extrac-
tion and summary analysis were computed by using
a software (MotionWare R version 1.1.20, Cambridge
Neurotechnology Ltd., Cambridge, UK) that employed
a validated sleep estimation algorithm [17]. Prior to data
analysis, they were visually inspected in order to reject
actigraphy artefacts (for example, any epochs where the
device had been removed).
The Sleep Start calculation was based upon the assumption
that the subject would have little or no movement in the
period shortly after they have fallen asleep. The period used
to determine sleep start was 10 minutes, hence at a 0.5 minute
epoch, we tested 20 epochs. The process then began by check-
ing the first 10 minute period following the bedtime. Each
epoch was tested against the threshold as described above.
The number of epochs exceeding the threshold was counted.
It the number of epochs exceeding the threshold was greater
than an allowed number dependent upon the epoch (for a
30 second-epoch the allowed counts above threshold were 2),
the process was repeated with the start point 1 minute forward
from the bedtime. This process continued until a 10 minute
block was found that satisfied both the threshold and allowed
counts criteria. The Sleep Start was thenmarked as the start of
this 10 minute period (CamNtech Ltd 2016). The Sleep End
calculation was similar to Sleep Start, except that the period
of 5 minutes (10 epochs for a 30 second-epoch) before the
get-up time that satisfied the test criteria was chosen in this
case (CamNtech Ltd 2016). The actigraphic assessment of
sleep was conducted before and after 1 month of treatment
with MPH and melatonin. The sleep parameters estimated
from actigraphic data are shown in Table 1.
Analyses were conducted using Statgraphics Centurion
version XVII (Stat point Technologies, Inc., Warrengton,
Virginia, US). Descriptive data were presented as standard
deviation (SD) means.
C. ARTIFICIAL NEURAL NETWORKS
In addition, we applied an advanced methodology based on
the use of artificial neural networks (ANNs) in order to tech-
nologically improve the interpretation of actigraphic data.
ANNs have the ability to derive meaning from complicated
or imprecise data and can be used to extract patterns and
detect trends that are too complex to be detected by either
humans or other computer techniques. They are inspired by
the biological nervous systems and are composed of a large
number of highly interconnected processing elements (neu-
rons) working in unison to solve specific problems. It is worth
mentioning that it has been recently found that the neurons
of some cortical regions of the human brain are organized
as densely connected components [25]. Other biological net-
works also exhibit the same kind of structure. Therefore,
it could be affirmed that ANNs that learn connected compo-
nents of neurons have a biological analogue.
ANNs can be used tomodel complex relationships between
inputs and outputs or to find patterns in data. Among their
advantages it is included abilities of adaptive learning, self-
organization, real time operation and fault tolerance via
redundant information coding [40]. They can be used for
a specific application, such as data clustering or classifi-
cation, through a learning process. Clustering is the unsu-
pervised classification of patterns (observations, data items,
or feature vectors) into groups (clusters) [27]. In our case,
we are interested in applying clustering to sleep patterns
based on actigraphic results. The Kohonen’s Self-Organizing
Map (SOM) [31] has been widely used as an ANN for
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TABLE 1. Sleep parameters considered for the analysis from the
actigraphic data set.
clustering tasks. Since the SOM’s proposal, many ANNs
based on self-organization have been proposed [32].
In order to identify and cluster sleep patterns from acti-
graphs in patients, a novel self-organizing neuralmodel called
the Growing Neural Forest (GNF) [49] has been utilized,
which has been implemented in MATLAB (TheMathWorks,
Inc., Madrid, Spain).1 This model is based on the Growing
Neural Gas (GNG) [19], which is a self-organizing based
model that learns a general graph with no special provisions
for data sets with separated clusters. However, the GNF
learns a set of trees of neurons so that each tree represents
a connected cluster of data. High dimensional datasets often
contain large empty regions among clusters, so this proposal
1Available online at http://www.lcc.uma.es/ejpalomo/software.html
is better suited to them than other self-organizing models
because it represents these separated clusters as connected
components made of neurons. In particular, the GNF is shown
to correctly discover the connected component structure of
some datasets. Moreover, the number of neurons are auto-
matically determined by the GNF/GNG models during the
unsupervised learning process according to input data, unlike
other unsupervised clustering methods such as SOM or K-
means. In our case, we make use of this model to identify and
cluster sleep patterns from actigraphs in patients.
Formally, a GNF is defined as a graph with a variable
number of nodes (neurons) and edges (connections). Nodes
are inserted and removed from the graph during learning
phase. Both nodes and edges are inserted and removed from
the graph during the learning process. The current number of
nodes is noted H . The training set for the graph is noted S,
with S ⊂ RD, where D is the dimension of the input space.
Each unit i ∈ {1, ...,H} has an associated prototype wi ∈ RD
and an error variable ei ∈ R, ei ≥ 0. Each connection has
an associated age, which is a non negative integer. The set of
connections is noted A ⊆ {1, ...,H} × {1, ...,H}, where no
self-connections are allowed, (i, i) /∈ A. It is also important
to notice that A is an undirected graph, i.e. one cannot have
(i, j) ∈ A and (j, i) /∈ A at the same time. An example of the
GNF architecture is given in Figure 1.
FIGURE 1. Structure of a GNF model with three subgraphs. The
connections which do not belong the spanning trees are shown with
dashed lines.
III. EXPERIMENTAL RESULTS
A. RESULTS WITH ACTIGRAPHY
Table 1 shows parameters description for every actigraphy
exploration performed. First column lists every of 28 acti-
graphic variable names analyzed in every exploration. Second
column shows results (median ED) from determined features,
that is, before starting treatment, actigraphic values were
taken in 27 children along seven days. Third column shows
results from actigraphy one month after starting treatment
with MTF (Metil-Fenidato), melatonin and additional nutri-
tion supplementary with oily acids from 1-3 serial.
Before treatment: Around 33% from patients (9/27)
showed values slightly higher in parameters mobility minutes
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TABLE 2. Parameter selection for the GNF and GNG models.
(between 57 and 168 minutes) and number of immobility
episodes (between 61 and 82 episodes). From this percentage,
more that 50% (5/9) also presented higher values to the
group average in parameters from sleep episodes (between
48 and 61 episodes) and fragmentation index (between 38%
and 73%), and values relatively lower than sleep efficiency
(between 76% and 79%). Around 67% (6/9) of our patients
recorded more than 40 night awakes, and latency times
between 20 and 30 minutes in 45% (4/9). Generally around
67% (6/9) from patients with altered values in actigraphic
parameters are straightly related with those that in daily
sleeps recorded sleeps awakes, higher conciliation times
and/or a lower resting sensation when awakes. A comparison
between total sleep time with daily real time with actigraphy
showed that total sleep time was overestimated in 15% of
patients (4/27). A patient whose mother referred somniloquia
showed higher scoring in mobility minutes and fragmenta-
tion indexes. Related to PSQ sleep questionnaire, 1 from
2 patients who answered positively more than 8 questions
were among those 9 individuals with altered actigraphic
parameters according to pre-treatment sample.
After treatment: One month after starting treatment with
MTF and melatonin, we appreciated that around 15% (4/27)
from total patients presented higher values in immobility
episodes (between 60 and 83 episodes) and sleep episodes
(between 48 and 61 episodes. These patients have presented
altered actigraphic values in main register.
B. APPLICATION OF THE GNF MODEL TO
ACTIGRAPHIC RESULTS
The GNF was trained with data resulting using actigraphs
under particular conditions. The obtained dataset hasM = 32
samples and a dimension ofD = 28 (please note that we have
high-dimensional data). An essential point when modeling
with neural networks is choosing the appropriate number of
neurons. For the GNF, the number of neurons is automatically
determined during the unsupervised learning process accord-
ing to input data. However, a maximum number of neurons
on the overall size of the network (Hmax) must be set. For our
experiments, the GNFwas trained with the actigraphic results
by setting the Hmax parameter to 5 and 10 neurons. Since the
GNF is based on the GNG, the GNF has the same parameters
than the GNG. Thus, the GNF parameter values have been set
to the values recommended in the original GNG paper [19],
which are given in Table 2.
Also, we have selected four subsets of features according
to key values:
TABLE 3. Prototype values for a GNF with 5 neurons and using the first
subset of features.
TABLE 4. Prototype values for a GNF with 5 neurons and using
the second subset of features.
TABLE 5. Prototype values for a GNF with 5 neurons and using the third
subset of features.
TABLE 6. Prototype values for a GNF with 5 neurons and using the fourth
subset of features.
TABLE 7. Prototype values for a GNF with 10 neurons and using the first
subset of features.
1) First subset includes assumed sleep time, real sleep
time and sleep efficiency.
2) Second subset contains real awake time, percentage
of real time awake, number of awakes and number of
falling sleep.
3) Third subset includes immobility minutes, percentage
of immobility time and number of falling sleeps.
4) Finally, fourth subset contains longer sleep and sleep
latency.
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TABLE 8. Prototype values for a GNF with 10 neurons and using
the second subset of features.
TABLE 9. Prototype values for a GNF with 10 neurons and using the third
subset of features.
TABLE 10. Prototype values for a GNF with 10 neurons and using the
fourth subset of features.
The values of the prototypes for the GNF trained with
5 neurons and the first, second, third and fourth subset of
actigraphic features, are shown in Tables 3-6, respectively,
for both groups of patients. Also, the same values are given
in Tables 7-10 for the GNF trained with 10 neurons and the
first, second, third and fourth subset of actigraphic features,
respectively. In these tables, every column represents one
feature from the corresponding subset of features from actig-
raphy and rows represent synaptic weights of every neuron
(prototypes), also known as cluster centroids.
The GNF results have been compared with those achieved
by two well-known ANNs used in unsupervised learning,
namely, the Growing Neural Gas (GNG) in which the GNF
is based on [19] and the Self-Organizing Map (SOM) [31].
These two ANNs represent the most outstanding models for
unsupervised learning. The GNG paremeter setup is the same
than the used for the GNF. The SOM has been trained using
the SOM Toolbox 2 for Matlab from the Helsinki University
2http://www.cis.hut.fi/somtoolbox/
FIGURE 2. Clustering results for each subset of features (rows) performed
by the following ANNs: (a) 5-neuron GNF, (b) 5-neuron GNG, and (c) 2 × 3
SOM. The prototype values are drawn as red circles, whereas input data is
plotted in blue. The two first principal components are plotted after
performing a PCA.
of Technology and setting its parameters to the default values.
The map sizes chosen for the SOM are 2 × 3 and 3 × 3
neurons to be as similar as possible to the number of neurons
of the GNF and GNG. The resulting prototypes for the GNF,
GNG and SOM models trained with two different number of
neurons and four subsets of features are shown in Figures 2
and 3. In these plots, prototype values are drawn as red
circles, whereas input data is plotted in blue. The two first
principal components are plotted after performing a PCA to
the input data and to the synaptic weight vectors given by the
trained GNF models. By observing these plots, we can see
that there is no difference among GNFs trained with 5 and
10 neurons, since prototypes are always placed in the same
place. Therefore, only one cluster was detected, so that input
data are similar among them and cannot be grouped in other
clusters.
In order to provide quantitative results, the mean squared
error (MSE), the Davis-Bouldin index (DBI), and the Dunn
index have been used to evaluate the clustering performance
of the three competitive models. The MSE, which is a mea-
sure of the intra-cluster variance that must be minimized in a






‖wi − xi‖2 (1)
whereM is the number of samples in the dataset, xi is the i-th
input sample and wi is the prototype of the winning neuron
corresponding to xi.
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FIGURE 3. Clustering results for each subset of features (rows) performed
by the following ANNs: (a) 10-neuron GNF, (b) 10-neuron GNG, and
(c) 3 × 3 SOM. The prototype values are drawn as red circles, whereas
input data is plotted in blue. The two first principal components are
plotted after performing a PCA.
The Davis-Bouldin index (DB) is a metric for evaluat-
ing clustering algorithms based on a ratio of within-cluster
and between-cluster distances. The Davis-Bouldin index is







where Dij is the within-to-between cluster distance ratio for





where d̄i is the average distance between each point in the
ith cluster and the centroid of the ith cluster; d̄j is the average
distance between each point in the ith cluster and the centroid
of the jth cluster; and the dij is the Euclidean distance between
the centroids of the ith and jth clusters.
The last considered performance measure is the Dunn




















A statistical significance study has been carried out for the
three considered quantitative performance measures, namely
TABLE 11. MSE, DBI and Dunn results for the 5-neuron GNF, 5-neuron
GNG and 2 × 3 SOM for each subset of features (S1, S2, S3, and S4). Best
results are in bold. Standard deviations are in parenthesis. Adjusted
p-values have been obtained after applying the Holm-Bonferroni method
with a 95% confidence level.
TABLE 12. MSE, DBI and Dunn results for the 5-neuron GNF, 5-neuron
GNG and 2 × 3 SOM for each subset of features (S1, S2, S3, and S4). Best
results are in bold. Standard deviations are in parenthesis. Adjusted
p-values have been obtained after applying the Holm-Bonferroni method
with a 95% confidence level.
MSE , DBI , and Dunn. The reported quantitative values
are the mean and standard deviation computed over the
10 runs corresponding to each competing method. Besides
that, the nonparametric Friedman test with the corresponding
post-hoc Dunn test are used to determine whether the dif-
ference of the best competing method with respect to all the
others is statistically significant. A 95% confidence level has
been chosen in all cases. Furthermore, the Holm-Bonferroni
method [56] has been applied and the corresponding adjusted
p-values have been obtained.
The GNF, GNG and SOM clustering results for each subset
of features (S1, S2, S3, and S4) are given in Tables 11 and 12
for the two different network sizes (5-neuron GNF/GNG,
2× 3 SOM and 10-neuron GNF/GNG, 3× 3 SOM), respec-
tively. Best results are in bold for each performance measure
and subset of features. Standard deviations are in parenthe-
sis. Note that results are very similar, although the GNF
obtains better results in general terms. As seen from the
Bonferroni-Holm adjusted p-values, none of the methods
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attains an average performance which is significantly better
than all the others, i.e. none of the adjusted p-values is lower
than 0.05.
IV. DISCUSSION
A. SLEEP IN CHILDREN WITH ADHD
An evaluation of sleep disorders in children can be afforded
from two different perspectives: using objective methods
(polysomnography, cardiorespiratory poligraphy, actigraphy,
etc) or by means of subjective methods. In these usually a
sleep survey is the element to evaluate. Both methods have
their own advantages and disadvantages. In this work me
made use of different subjective procedures (daily report,
sleep survey) and other objective one (actigraphy), and addi-
tionally we have introduced the ANN of GNF type. Only
few reviews exist to evaluate the sleep in children that are
receiving treatment which only evaluate somnolence as the
unique sleep disorder derived from using particular drugs
on [46]. In this work, we used a reduced version and adapted
from the Pediatric Sleep Questionnaire (PSQ) [9] that allows
evaluate through 22 questions insomnia, day somnolence,
parasomnias, breathing disorders related with sleep and resis-
tance to go to bed. This leads us to use a quick questionnaire
in pediatric consult to evaluate the sleep in patients under
treatment during a longer period. Particularly, in our case we
established onemoth since it is themost frequent periodwhen
sleep disorders are expressed. ADHD association studies
sleep disorders (TS) and frequently some factors are related
with sleep disorders as executive structure alterations within
ADHD [33], [50], breathing disorders during sleeping, inter-
active environmental conditions between sleep and ADHD,
treatment with drugs for this disorder, children sleep features,
among others.
Cortese [10] work on a metanalysis with ADHD and sleep
disorders in children that collected studies both from objec-
tive parameters (polysomnography and/or actigraphy) and
subjective ones (questionnaires) published between 1987 and
2008. The conclusion established is that according to subjec-
tive indicators, ADHD affected children present more sleep
disorders (sleep and awakes) than others. Objective indicators
revealed sleep fragmentation, poor sleep efficiency, breathing
disorders while sleeping and excusive day somnolence. Some
works [4], [11] refers to sleep disorder affecting more than
50% of families with ADHD affected children, mainly dif-
ficulties to start sleeping and to keep sleeping with frequent
awakes. An epidemiologic study with ADHD and TS [63]
was performed in Spain, this showed an associated snoring
(more than half of the night), enuresis, difficulty to keep
sleep (more than two awakes per night), resistance to go
to bed and rhythm movement disorders. It is important to
mention that sleep disorders are added factors that limit life
quality in these children and their families [60]. Main cause
of sleep disorders in children with ADHD is complex and
broadly unknown. We defend that this field requests more
research to understand the complex relation existing between
sleep and ADHD. In this line, we have to consider several
specific causes that take part in this relation: 1) Resistence
to go to sleep. 2) Stimulant ingestion substances as coffee,
tea, chocolate, carbonated drinks y psychostimulant drugs
used in ADHD. 3) Suffering other affections. Anxiety and
depression disorders can bring difficulties to sleep, and these
are illnesses frequently related to ADHD. Both diversity of
causes, multiplicity of sleep disorders included in Interna-
tional Classification of Sleep Disorders ICSD [15] related
with children and difficulties to define and interpret each of
them in ADHD affected children lead to go on searching pro-
cedures and techniques, as ANN, to simplify how to interpret
different cases in a more efficient, accurate and reliable way.
B. ACTIGRAPHY
Currently polysomnography is considered as ’’gold stan-
dard’’ method to study sleep disorders. However, imple-
menting this method on children presents some issues as,
it leads to cost in budget, its adaptation in younger children
presents problems, relevant difficulties in children affected
with particular pathologies (ADHD, autism, cerebral palsy,
etc), children with frequent and important TS [12], [39], [54].
Recently, to supply these deficiencies and its demonstrated
reliability and efficiency this methodology is being applied
on child population [64]. This procedure has been proven as
easy, cost afforded, and highly reliable [23], [41]. Actigra-
phy determines sleep and awake evaluation along multiple
days, this is the reason why are used in sleep disorders,
circadian rhythms and insomnia [2], [38]. Nevertheless, other
disorders exist that can be useful to monitor the evolution of
Restless Legs Syndrome (RLS) or periodical movements in
limbs61. American Academia of Sleep Medicine (AASM)
recommends to apply actigraphy [15]. 1) Sleep disorders
evaluation. 2) Assessment of response to sleep disorder treat-
ment. 3) In special situations as children, where to perform
a polysomnography and or interpret it is highly difficult and
tedious and exponentially increasing, in these cases actigra-
phy becomes an important alternative. Children sleep unit
from Paediatric department at University of Granada had
taken efficient results in applying actigraphy on children,
but in particular cases it presents deficiencies to interpret
concrete responses to new treatments and classification sys-
tems. This approach is focused on a combined usage of MTF
able to transitory cause sleep disorders when is administered
to ADHD and aMT affected children. Actigraphy per se is
potentially useful to numerically quantifies and compares
params in ADHD affected children. However, this is not
sufficiently powerful since it is difficult to accurately define
whether sleep patterns aremodified after the treatment. Fortu-
nately, ANN provides the appropriate tool to establish groups
to define particular groups of variables that define a concrete
pathology and different ways to make sick in the context of
sleep disorders.
Indeed, we have implemented different ANNmodels using
important referent parameters. Results fromANN application
in this context are inspiring since these conclude that the
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impossibility to differentiate patients before and after being
medicated. This plays and important role in clinic because
it opens new fields on children in which specific medication
for ADHD and sleep disorders are problems that alter daily
activities and academicals in those patients.
C. METIL-FENIDATO
Recently an important increasing in the use of MTF in
children population is happening [37], [42], for this reason
is relevant deeply know their secondary effects. Different
mechanisms have been described to explain this relation; by
straight pharmacological effect, by sleep disorders patterns
(i.e. knigthmares), by exacerbation of a previous disorder or
finally triggering somnolence [43]. We highlight the fact that
this is a field to be defined this arouses important interest to
find new drugs as substitutes and less secondary effects [44].
Franco et al. presents a broad review of 393 ADHD affected
children are treated with MTF compared with placebo, they
conclude that treated children are negatively affected in their
sleeps [13]. These results coincide with presented by Soutullo
and Buñuel who aim that applyingMTF in children decreases
appetite and negatively affects sleep. Ross and Ross [53].
defends that collateral effects of administrating psychostim-
ulants, at short term, tends to be insomnia and anorexia and
generally are short term long. These effects use to be frequent
during the first month, this is the reason why our project was
performed in this transition phase. In this sense, we highlight
the fact that in our patients the percentage of children with
appetite disorders and loss of weight was 33% (9/27).
D. MELATONIN
A combined administration of MTF and melatonin is one of
the most novelty aspects of this work. Melatonin presents an
important action as antioxidant [18], [48], [52], as well as it
plays an important role in sleep disorders in children with
different clinic problems [47]. This experiment has proved
how possible secondary effects of applying MTF during the
first month are observed. Moreover, children were treated
with a relevant improvement in their sleep quality. In this
case, melatonin dose was 1 mg. Currently we have a cohort of
patients with a longer period of treatment with 3 mg of mela-
tonin administered. These results together with a combined
administration of fatty acids, MTF and melatonin lead to
think of important benefits on life quality in ADHD affected
children.
E. ARTIFICIAL NEURAL NETWORKS
As it was previously described, we present an ANN called
Growing Neural Forest (GNF) to perform a clustering task for
data extracted from children under treatment and not treated
children. ANNs are powered tool as classifier and provide
advantages to perform quantitative tests in medical practice.
Medical records contain valuable information to be use for
designing and training ANN to enrich diagnosis in general
medicine and offers new perspectives to specialist doctors.
Most interesting approach of applying ANN, from a clinical
point of view, brings with the possibility to study set of data
and variables simultaneously to classify particular situations
not considered a priori. This is potentially powerful not just
for general sleep disorders but for particular sleep disor-
ders. Indeed, ANNs have been broadly applied in different
fields [1], [5], [25], [65].
GNF results showed the impossibility to classify patients
as treated and not treated according to input data, then as a
result we had that sleep was not affected by administrating
drugs (MFT and melatonin). These results demonstrate that
melatonin attenuated possible sleep disorders induced by
psychostimulant drugs in patients with ADHD. Moreover,
the Growing Neural Forest (GNG) and the Self-Organizing
Map (SOM) have been used to provide comparative results.
The GNG and SOM results are similar to those achieved by
the GNF according to the obtained adjusted p-values with the
Holm-Bonferroni method. Thus, these results corroborates
that a combined use of melatonin andMTF can keep and even
improve in some cases sleep pattern in ADHD affected chil-
dren. Therefore, ANNs open new expectations for ongoing
TS and ADHD in children as it was proven.
V. CONCLUSION
In this paper, we have used a novel ANN model called the
Growing Neural Forest (GNF) that concludes the impossi-
bility to differentiate patients before and after being med-
icated for ADHD. GNF results have been compared with
those achieved by another two ANNs also used in unsuper-
vised learning, namely the Growing Neural Gas (GNG) and
the Self-Organizing Map (SOM). These ANNs showed the
impossibility to classify patients as treated and not treated
according to input data, then as a result we had that sleep was
not affected by administrating drugs (MFT and melatonin).
Data clustering performed by the ANNs demonstrated that
melatonin attenuated possible sleep disorders induced by
psychostimulant drugs in patients with ADHD. Melatonin
presents an important action as antioxidant playing an impor-
tant role in sleep disorders in children with different clinic
problems. We concluded that possible secondary effects of
applying MTF during the first month are observed. Ongoing
work includes an extension of data for training the ANNs
from a higher number of patients to extract more information
and to study the possible emerging of different profiles of
patients. This fact becomes the ANN methodology as an
important tool really useful for future works in this field.
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